Professional Documents
Culture Documents
guidance for
sponsors
Mamoon Rashid and Fakhrul
Ahsan
cont
Methods
Solubility
Based on highest dose strength of an IR
product.
Highly soluble means, highest dose is soluble
in 250 mL or less amount of aqueous medium in
pH range of 1 to 7.5.
250 mL = 8 ounce = 1 glass of water
Permeability
Is based indirectly on the extent of absorption
(fraction of dose absorbed) in human
Directly on measurements of the rate of mass
transfer across human intestinal membrane.
Alternative non-human systems available
Methods (cont.)
Dissolution:
Rapidly dissolving means no less than 85% of
the labeled drug is dissolved within 30 minutes
using apparatus I at x rpm, or apparatus II at y
rpm.
In a medium of
0.1 N HCl or Simulated Gastric Fluid USP
without enzymes;
a pH 4.5 buffer; and
a pH 6.8 buffer or Simulated Intestinal Fluid
USP without enzymes.
us I or II
?
100
1 n
2
1 Rt Tt
n t 1
What is
the
highest
value of f2?
Excipients
can sometimes affect the rate and extent of
drug absorption.
To support a biowaiver request, the quantity
of excipients in the IR drug product should
be consistent with the intended function (e.g.,
lubricant).
When new excipients or atypically large
amounts of commonly used excipients are
included, additional information documenting
the absence of an impact on BA of the drug may
be requested by the Agency. Such information
can be provided with a relative BA study using a
REGULATORY APPLICATIONS
OF THE BCS
INDs/NDAs
REGULATORY APPLICATIONS OF
THE BCS
ANDAs
REGULATORY APPLICATIONS OF
THE BCS
Post-approval Changes
BCS-based biowaivers can be requested for
significant postapproval changes to a rapidly
dissolving IR product containing a highly
soluble, highly permeable drug substance,
provided that dissolution remains rapid for the
postchange product and both pre- and
postchange products exhibit similar
dissolution profiles.
DATA TO SUPPORT A
REQUEST FOR
BIOWAIVERS
Part II
Guideline for
preparing Biowaiver
monographs
What is a monograph?
By definition, monograph is a detailed and
documented treatise on a particular
subject.
Objectives of the monograph:
ONE: Gather and organize all relevant data
on a particular API, which have to be taken into
consideration when
A decision is to be made as to whether a new
formulation of that API (either a
reformulation or a new, multi-source
product) needs to be tested in an in vivo
bioequivalence study, or whether a biowaiver
Objectives (cont.)
So, what are those relevant data?
Solubility, pharmacokinetics (especially with
respect to absorption and bioavailability) and
permeability of the API and the dissolution of
dosage forms as per current BCS rules;
Therapeutic use and therapeutic window of the
API; any history of problems with BA/BE and, if it
exists, data on excipient interactions. In specific
cases, it may be desirable to introduce and
discuss further information relevant to a
biowaiver decision.
The risks associated with an inappropriate
biowaiver decision will be addressed.
Objectives (cont.)
TWO:
To assess the validity of the present BCS
Guidances on the basis of the gathered data. To
illustrate some of the possibilities: the results
may show that there is a need to re-define the
present BCS Classes (e.g. relax permeability
requirements or D:S limits), to invoke other
dissolution test conditions than those currently
recommended or to change the specifications
used for dissolution test results
THREE:
To assess the biopharmaceutical relevance
of dissolution testing according to the
compendial method in the USP (where one
Sourcing
cont.
Title
Abbre
v.
Organization of the
monograph
Biowaiver Monographs for Immediate
Release Solid Oral Dosage Forms:
xxxx
BCS Biopharmaceutics Classification
System
IR Immediate Release
MA Marketing Authorization
BE Bioequivalence
GI Gastrointestinal
API Active Pharmaceutical
Ingredient
BA Bioavailability
DEGermany
NL The Netherlands
Organization
Abstr
act
cont.
Suggested:
API;
Absorption;
Biopharmaceutics Classification
System (BCS); Permeability;
Solubility.
Indicati
on
Polymorphism
Partition coefficient
State which organic solvent was used to determine logP. If only
the distribution coefficient (logD) is known, give this with the
pH value at which it was determined.
Available dose/tablet
WHO recommended dose.
Strengths available on studied market(s) and special
dosing Instructions (e.g. with food) on that market
Name the market(s) that were studied.
Dissolution
USP dissolution methodology
Comparative studies of different formulations in
vitro
Known attempts to optimize dissolution from the
dosage form:
e.g. micronization of drug, addition of surfactants to
formulation.
Discussion
Solubility
Discuss quality of the data
D:S ratios for maximum available dosage strength
and for WHO dosage strength
Any D:S changes with pH?
Conclusion about classification with respect to
solubility according to the current BCS criteria
in
bio
equivalencies among products
already in the marketplace?
Conclusion
BCS classification for API under the present BCS
rules
Stipulate degree of certainty of classification.
Can a biowaiver be
recommended?
Under which restrictions?
Where applicable, comment on current BCS rules
and class boundaries
What are the risks associated with associated with
cont.
Part III
Case
studies